

GI ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS			
SWOG	S1613-mCRC, Adv/Met, TP vs CETIRI	1	Y 0 Screening	130	99	99	72	36	14	2	11/27/2017	329	127
					99	99	72	36	14	2			
		2	Y 1 Trastuzumab + Pertuzumab 2 Cetuximab + Irinotecan	130	5	5	3	1	1	0	11/27/2017		
					6	6	5	2	0	0			
					11	11	8	3	1	0			
		3	Y 3 Crossover: Trastuz + Pertuz	130	2	2	2	1	0	0	11/27/2017		
					2	2	2	1	0	0			
Yes	A021502-Colon, Stg III, Chemo +/- Atezol, ATOMIC	1	E Total Registrations		7	7	4	2	1	0	03/23/2018	120	45
					7	7	4	2	1	0			
	N1048-Rectal,LocalAdv,ChemoRT+/-FOLFOX	1	E Total Registrations		165	33	16	9	2	2	06/05/2013	362	157
					165	33	16	9	2	2			
No	A021501-Adeno Panc,Borderline Resect,Chemo vs ChemoRT	0	E Total Registrations		18	7	0	0	0	0	05/01/2017	91	36
					18	7	0	0	0	0			
		1	E Total Registrations		15	5	0	0	0	0	05/01/2017		
					15	5	0	0	0	0			
	EA2142-GI NEC, Adv G3, EP vs TMZ + CAP	1	E Total Registrations		4	0	0	0	0	0	07/14/2016	197	77
					4	0	0	0	0	0			
	EA2161-PANC, Adv Rapalog Resistant PNETs, MLN0128	1	E Total Registrations		1	1	1	1	0	0	09/06/2018	27	7
					1	1	1	1	0	0			
	EA2165-Anal, Stg II-III, Nivolumab after CMT	1	E Total Registrations		1	1	1	1	0	0	10/09/2018	28	11
					1	1	1	1	0	0			
	NRGGI002-Rectal, Ph II, Sensitization using TNT	1	E Total Registrations		12	9	6	6	5	0	02/21/2017	352	148
					12	9	6	6	5	0			
	NRGGI004-Colorectal, Stg IV, dMMR Immuno-Therapy	1	E Total Registrations		4	4	3	2	1	0	04/18/2018	118	41
					4	4	3	2	1	0			